Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to the most-rare conditions, there isn’t even a pipeline.
CRISPR Success in Single Baby Highlights Rare Disease ‘Crisis’ Read More »
Drugmakers will be expected to commit to aligning U.S. prices with the lowest price set in a group of peer nations for all brand products across all markets that do not currently have generic or biosimilar competition.
New Details From Trump’s Drug Pricing Effort Put Branded Drugs in the Crosshairs Read More »
TD Cowen, Raymond James and Bank of America have all downgraded UnitedHealth’s stock, citing dogged internal challenges facing the company.
Self-collection correctly identified 95.2% of HPV samples that are associated with increased cancer risk.
Teal posts data on newly approved at-home cancer screening device Read More »
The Most Favored Nation order is unlikely to deliver broad, sustained savings without triggering legal challenges, administrative friction and unintended consequences for both the healthcare sector and patient access.
Understanding What Trump’s MFN Executive Order Can and Can’t Do Read More »
The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets to express confusion regarding the pharma’s overall strategy.
Pfizer Puts $6B on the Line For 3SBio’s PD-1/VEGF Antibody Read More »
In an interview on Friday, FDA Commissioner Marty Makary threw his weight behind psychedelic therapies, noting that patients taking these substances experience significant benefits for various neuropsychiatric conditions.
Makary Backs Psychedelics for Neuropsych, Promises Speedy Review Read More »
While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.
Women’s health faces growing headwinds, despite jump in venture investment Read More »
The late-stage results come in advance of pivotal data that Ionis expects to provide for its antisense oligonucleotide Tryngolza in the third quarter, building up toward a regulatory submission in hypertriglyceridemia by year-end.
Ionis Builds Triglyceride-Lowering Case for RNA-Targeting Tryngolza Read More »
The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.
CRISPR Expands Focus, Pays Up To $95M in Sirius’ siRNA Pact Read More »
